These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Special report: treatments for castration-resistant metastatic prostate cancer. BlueCross BlueShield Association Technol Eval Cent Assess Program Exec Summ; 2013 Apr; 27(7):1-4. PubMed ID: 23865104 [No Abstract] [Full Text] [Related]
9. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways. Pal SK; Twardowski P; Josephson DY Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987 [TBL] [Abstract][Full Text] [Related]
10. Metastatic castration-resistant prostate cancer: time for innovation. Tucci M; Scagliotti GV; Vignani F Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785 [TBL] [Abstract][Full Text] [Related]
11. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer? Albiges L; Loriot Y; Massard C; Fizazi K Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192 [No Abstract] [Full Text] [Related]
12. [The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer]. Kosaka T; Oya M Nihon Rinsho; 2012 Nov; 70 Suppl 8():353-9. PubMed ID: 23513865 [No Abstract] [Full Text] [Related]
13. Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. De Maeseneer DJ; Van Praet C; Lumen N; Rottey S Urol Oncol; 2015 Jul; 33(7):310-21. PubMed ID: 25708954 [TBL] [Abstract][Full Text] [Related]
14. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results]. Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737 [TBL] [Abstract][Full Text] [Related]
15. [New drug treatment possibilities in castration resistant prostate carcinoma]. Meisel A; Stenner F Praxis (Bern 1994); 2012 Sep; 101(18):1143-9; quiz 1150-1. PubMed ID: 22945814 [No Abstract] [Full Text] [Related]
16. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks. Lieberman R Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618 [No Abstract] [Full Text] [Related]
17. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Bedoya DJ; Mitsiades N Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426 [No Abstract] [Full Text] [Related]
18. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer. Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A Int J Clin Oncol; 2019 Jul; 24(7):842-847. PubMed ID: 30739263 [TBL] [Abstract][Full Text] [Related]
19. Targeting the androgen receptor in prostate cancer. Culig Z Expert Opin Pharmacother; 2014 Jul; 15(10):1427-37. PubMed ID: 24890318 [TBL] [Abstract][Full Text] [Related]
20. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]